Diagnostics Sector

Diagnostics Sector Overview

The note compares India’s diagnostics market and six diagnostic chains: Dr. Lal Pathlabs, Metropolis Healthcare, Krsnaa Diagnostics, Thyrocare Tech., Vijaya Diagnostics and Suraksha Diagnostics. It covers market size and mix, operating parameters, testing charges, historical financials, target prices, valuation multiples and shareholding. Agilus Diagnostics and Apollo Labs are categorized as hospital labs and excluded from the study.

Key Findings

• Market mix: For FY24, hospital labs accounted for 36-40% of the market, standalone centers 35-39%, and diagnostic chains 20-24%. Regional chains represented 62-66% of the diagnostic-chain mix, compared with 34-38% for multi regional chains.
• Chain market shares: The report lists Dr. Lal Pathlabs at 11.7% market share, Metropolis Healthcare at 6.3%, Krsnaa Diagnostics at 3.3%, Thyrocare Tech. at 3.0%, Vijaya Diagnostics at 2.9% and Suraksha Diagnostics at 1.1%.
• Different operating profiles: In Q3 FY2025, reported patients ranged from 0.23 Mn. for Suraksha Diagnostics to 6.9 Mn. for Dr. Lal Pathlabs. Revenue per patient ranged from INR 373 for Thyrocare Tech. to INR 1,616 for Vijaya Diagnostics; the report notes that Krsnaa Diagnostics’ data was not reported in this format.
• Revenue growth varies: FY24 operating revenue ranged from 219 Cr. for Suraksha Diagnostics to 2,227 Cr. for Dr. Lal Pathlabs. In 9M-FY25, year-on-year revenue growth was 29% for Vijaya Diagnostics, 20% for Thyrocare Tech. and 11% for Dr. Lal Pathlabs, among the companies with figures shown.
• Testing prices differ: The report’s comparison of 11 common tests ranks Krsnaa Diagnostics as the least expensive on cumulative testing costs and Suraksha Diagnostics as the most expensive. The ranking is based on the cumulative costs of the tests shown.
• Margins and cash conversion are mixed: For 9M-FY25, EBITDA margins shown ranged from 24.4% for Metropolis Healthcare to 40.2% for Krsnaa Diagnostics. CFO / EBITDA for 6M-FY25 ranged from 21% for Krsnaa Diagnostics to 98% for Thyrocare Tech.

Company Target Prices and Upside

The report provides company-level CMP, target price and upside estimates, but does not state an overall sector verdict or a valuation method for these targets.

Key Risks

• Krsnaa Diagnostics receivables: Krsnaa primarily operates under a PPP model. Receivables for 6MFY25 were high due to delayed payment from Himachal Pradesh and Karnataka; management expects trade receivables to normalize in FY26.
• Profitability after Covid revenue normalization: The report attributes a FY23 year-on-year revenue decline and lower profitability in the period discussed to normalization of Covid revenues, higher lab expenses and operating costs.
• Company estimates: The report notes that Suraksha Diagnostics estimates are based on management guidance and preliminary internal assessment.

Our View

The note highlights projected market growth and a faster growth rate for radiology than pathology, while showing meaningful differences in chain scale, margins, pricing and target-price upside. It does not make a single sector recommendation; investors should consider the company-specific estimates and risks presented.

Standard disclosures:

• Research Analyst has served as an officer, director or employee of subject company(ies): No
• We or our associates have received compensation from the subject company(ies) in the past 12 months: No
• We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past12 months: No
• We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months –No
• We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report –No
• We or our associates or Research Analyst or his/her relative's financial interest in the subject company(ies)- No
• Nature of financial interest in subject company, if any –Nil
• We, our associates or Research Analyst have actual/beneficial ownership of 1% or more securities of the subject company (ies) at the end of the month immediately preceding the date of publication of Research Report – No
• Subject company (ies) may have been client during twelve months preceding the date of distribution of the research report-No
• We or our Associates or Research Analyst are engaged in market making of subject company – No
• By referring to any particular sector, Minerva Capital Research Solutions does not provide any promise or assurance of favorable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.
• There are either no material conflict of interests or all existing and potential conflict of interest are disclosed herein.

Regulatory disclosures:

• Minerva Capital Research Solutions is an independent investment advisory firm founded by Nishant Gupta(SEBI registration no. INH000018896).
• Registration granted by SEBI and certification from NISM in no way promise or guarantee that the research recommendation will provide any assured, minimum or risk-free return to the investors.
• The research report serves as general information and does not account for individual investment goals, financial situations, or needs. Minerva Capital Research Solutions strives to provide reliable and comprehensive information, sourced from what are believed to be trustworthy channels. However, this information has not been independently verified by Minerva Capital Research Solutions or its analysts, and no guarantees are made regarding its accuracy or completeness. The opinions expressed in this report reflect the views of the research analyst at the time of publication and may change over time. Minerva Capital Research Solutions and its affiliates as on date of publication of this report may or may not hold any positions in the securities discussed. The views presented are general and do not consider individual risk tolerance or investment objectives; therefore, readers should seek independent professional advice before making investment decisions. Minerva Capital Research Solutions does not guarantee a favorable outlook for any specific industry or sector and urges investors to consider all relevant risk factors, including their financial circumstances, before investing. The analyst certifies that their views accurately represent their personal opinions on the companies discussed and that no part of their compensation is tied to specific recommendations made in this report. This material should not be interpreted as an offer or solicitation to buy or sell securities in jurisdictions where such offers would be illegal. Consequently, brokerage and investment services described herein are not available to Canadian or U.S. persons. Distribution outside India requires prior written consent. This Research Report assumes that the recipient will assume all risks associated with its contents. If there are any disagreements or dissatisfaction with this report or its disclaimer, the only recourse is to cease using it. Minerva Capital Research Solutions and its affiliates will not be liable for any direct or indirect losses resulting from the use of this report. Recipients are required to adhere to these restrictions. The material is for the personal use of authorized individuals and does not constitute a solicitation or offer to buy or sell any securities in jurisdictions where such actions would be illegal.
• For any queries or grievances: Mr. Nishant Gupta | Email: nishant.gupta@mcapital.in | Contact Number: 8171433387 | Website: www.mcapital.in